



## PTC Therapeutics to Participate at Upcoming Virtual Investor Conferences

April 27, 2021

SOUTH PLAINFIELD, N.J., April 27, 2021 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that management will present a company overview at the following conferences:

BofA Securities 2021 Virtual Health Care Conference  
Tuesday, May 11<sup>th</sup> at 8:45 a.m. ET

2021 RBC Capital Markets Global Healthcare Virtual Conference  
Tuesday, May 18<sup>th</sup> at 10:20 a.m. ET

2021 UBS Global Healthcare Virtual Conference  
Wednesday, May 26<sup>th</sup> at 12:00 p.m. ET

The presentations will be webcast live on the Events and Presentations page under the investor relations section of PTC Therapeutics' website at <https://ir.ptcbio.com/events-presentations> and will be archived for 30 days following the presentation. It is recommended that users connect to PTC's website several minutes prior to the start of the webcast to ensure a timely connection.

### About PTC Therapeutics, Inc.

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and our mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.

### FOR MORE INFORMATION PLEASE CONTACT:

**Media:**

Jane Baj  
+1 (908) 912-9167  
[jbaj@ptcbio.com](mailto:jbaj@ptcbio.com)

**Investors:**

Kylie O'Keefe  
+1 (908) 300-0691  
[kokeefe@ptcbio.com](mailto:kokeefe@ptcbio.com)

 View original content: <http://www.prnewswire.com/news-releases/ptc-therapeutics-to-participate-at-upcoming-virtual-investor-conferences-301276912.html>

SOURCE PTC Therapeutics, Inc.